Krystal Biotech (KRYS) Current Leases (2019 - 2026)

Krystal Biotech (KRYS) has 8 years of Current Leases data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 32.16% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 32.16% YoY), and the FY2025 full-year result was $1.8 million, up 45.52% from the prior year.
• Current Leases climbed to $1.8 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.8 million in Q1 2026 to a low of $1.2 million in Q4 2024.
• A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases soared 117.75% in 2022 and retreated 17.44% in 2024, its largest moves.
• Tracing KRYS's Current Leases over 5 years: stood at $1.6 million in 2022, then dropped by 5.57% to $1.5 million in 2023, then dropped by 17.44% to $1.2 million in 2024, then surged by 45.52% to $1.8 million in 2025, then increased by 1.64% to $1.8 million in 2026.
• Business Quant data shows KRYS's Current Leases at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.7 million in Q3 2025.